News >

Markman Reflects on Career, Progress in Gynecologic Cancers

Brandon Scalea
Published: Monday, Oct 29, 2018

Maurie Markman, MD

Maurie Markman, MD
The treatment paradigm of gynecologic malignancies is expanding with approved targeted agents and a greater focus on maintaining quality of life (QoL). According to Maurie Markman, MD, the field is moving in a precision-based medicine direction.

, Markman reflected on practice-changing advances during his career and discussed the future of gynecologic cancer treatment.

OncLive: You received the 2018 Giants of Cancer Care® award in Gynecologic Cancer. What are your thoughts on winning this award?

Markman: Obviously, I have somewhat of a unique perspective on the Giants of Cancer Care® since I had the privilege of being involved with the program from the beginning, both as chair and as a member of the committee. I'm very aware of the extraordinary effort that goes into exactly what it says: peer-nominated, peer-selected, and the awards are really meant to say, "Your peers have looked at you as having an impact in the field and on patients."
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Consultations® in Ovarian Cancer: Differentiating Among Clinical Trial Designs to Match PARP to PatientOct 31, 20191.5
Cancer Summaries and Commentaries™: Update from Munich: Advances in the Treatment of Lung Cancer, Genitourinary Malignancies, and Gynecologic MalignanciesDec 30, 20192.25
Publication Bottom Border
Border Publication
x